Is JAZZ or JUNS more undervalued in 2026?

CirclFi compares Jazz Pharmaceuticals plc (JAZZ) and Jupiter Neurosciences, Inc. (JUNS) using 13 institutional-grade valuation models. JAZZ has a Quality of Company score of 7.5/10 while JUNS scores 4.7/10.

Which is a better buy — JAZZ or JUNS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JAZZ and JUNS valuations compare?

JAZZ at $236.49 and JUNS at $0.26 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JAZZ vs JUNS Valuation Comparison 2026 — Intrinsic Value Analysis

JAZZ

Pharmaceutical Preparations

Jazz Pharmaceuticals plc

Quality

7.5

out of 10

Value Trap

SAFE

Price

$236.49

Last close

Models

12/13

Active

JUNS

Pharmaceutical Preparations

Jupiter Neurosciences, Inc.

Quality

4.7

out of 10

Value Trap

—

Price

$0.26

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	JAZZ Fair Value	JAZZ Upside	JUNS Fair Value	JUNS Upside
Bayesian DCF	Intrinsic	$352.09	+48.9%	$0.10	-60.6%
Earnings Power Value	Intrinsic	—	—	$0.02	-94.6%
EROIC Spread	Intrinsic	$108.93	-44.6%	$0.39	-0.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JAZZ vs JUNS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JAZZ vs JUNS — Which Stock Is More Undervalued?

JAZZ scores higher with a 7.5/10 quality rating vs JUNS's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jazz Pharmaceuticals plc (JAZZ) and Jupiter Neurosciences, Inc. (JUNS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JAZZ currently trades at $236.49 with a QOC of 7.5/10, while JUNS trades at $0.26 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).